Venus Concept Inc (VERO)
0.726
+0.03 (+3.66%)
USD |
NASDAQ |
May 20, 16:00
0.73
0.00 (0.00%)
After-Hours: 20:00
Venus Concept Gross Profit Margin (Quarterly): 67.27% for March 31, 2022
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2022 | 67.27% |
| December 31, 2021 | 69.98% |
| September 30, 2021 | 70.46% |
| June 30, 2021 | 72.47% |
| March 31, 2021 | 67.42% |
| December 31, 2020 | 64.70% |
| September 30, 2020 | 65.30% |
| June 30, 2020 | 70.00% |
| March 31, 2020 | 63.96% |
| December 31, 2019 | 61.99% |
| September 30, 2019 | 71.76% |
| June 30, 2019 | 41.62% |
| Date | Value |
|---|---|
| March 31, 2019 | 54.45% |
| December 31, 2018 | 38.60% |
| September 30, 2018 | 44.73% |
| June 30, 2018 | 54.08% |
| March 31, 2018 | 36.36% |
| December 31, 2017 | 47.11% |
| September 30, 2017 | 40.77% |
| June 30, 2017 | 39.77% |
| March 31, 2017 | 43.54% |
| December 31, 2016 | 38.90% |
| September 30, 2016 | 34.60% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
36.36%
Minimum
Mar 2018
72.47%
Maximum
Jun 2021
57.14%
Average
62.98%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Zymeworks Inc | -- |
| Aurinia Pharmaceuticals Inc | 98.82% |
| Edesa Biotech Inc | -- |
| Lexaria Bioscience Corp | 79.16% |
| Liminal Biosciences Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -63.56% |
| Return on Assets | -15.27% |
| Return on Invested Capital | -19.71% |
| Profit Margin (Quarterly) | -32.64% |
| Operating Margin (Quarterly) | -28.16% |
| Return on Net Operating Assets | -23.06% |